Dogwood Therapeutics, Inc. (DWTX) Press Releases https://ir.dwtx.com/news/press-releases/rss Please specify a description for this RSS Feed en-us https://d1io3yog0oux5.cloudfront.net/_9f55823e9477de6aca19e5bcf0d048d4/virios/files/theme/images/DogwoodLogo.png Dogwood Therapeutics, Inc. Logo Equisolve Investor Relations Suite <![CDATA[Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial]]> https://ir.dwtx.com/news/press-releases/detail/161/dogwood-announces-completion-of-enrollment-in-ongoing Mon, 14 Sep 26 08:45:00 -0400 https://ir.dwtx.com/news/press-releases/detail/161/dogwood-announces-completion-of-enrollment-in-ongoing <![CDATA[Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026]]> https://ir.dwtx.com/news/press-releases/detail/160/dogwood-to-host-virtual-kol-event-to-discuss-halneuron Mon, 17 Aug 26 08:30:00 -0400 https://ir.dwtx.com/news/press-releases/detail/160/dogwood-to-host-virtual-kol-event-to-discuss-halneuron <![CDATA[Dogwood Therapeutics Announces Second Quarter 2026 Financial Results]]> https://ir.dwtx.com/news/press-releases/detail/159/dogwood-therapeutics-announces-second-quarter-2026 Thu, 13 Aug 26 08:30:00 -0400 https://ir.dwtx.com/news/press-releases/detail/159/dogwood-therapeutics-announces-second-quarter-2026 <![CDATA[Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026]]> https://ir.dwtx.com/news/press-releases/detail/158/dogwood-enrolls-first-200-patients-in-ongoing-halneuron Mon, 20 Jul 26 08:30:00 -0400 https://ir.dwtx.com/news/press-releases/detail/158/dogwood-enrolls-first-200-patients-in-ongoing-halneuron <![CDATA[Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board]]> https://ir.dwtx.com/news/press-releases/detail/157/dogwood-therapeutics-appoints-iain-dukes-venture-partner Tue, 30 Jun 26 08:45:00 -0400 https://ir.dwtx.com/news/press-releases/detail/157/dogwood-therapeutics-appoints-iain-dukes-venture-partner <![CDATA[Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study]]> https://ir.dwtx.com/news/press-releases/detail/156/dogwood-therapeutics-announces-commencement-of-halneuron Mon, 18 May 26 08:45:00 -0400 https://ir.dwtx.com/news/press-releases/detail/156/dogwood-therapeutics-announces-commencement-of-halneuron <![CDATA[Dogwood Therapeutics Announces First Quarter 2026 Financial Results]]> https://ir.dwtx.com/news/press-releases/detail/155/dogwood-therapeutics-announces-first-quarter-2026-financial Thu, 14 May 26 08:30:00 -0400 https://ir.dwtx.com/news/press-releases/detail/155/dogwood-therapeutics-announces-first-quarter-2026-financial <![CDATA[Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026]]> https://ir.dwtx.com/news/press-releases/detail/154/dogwood-therapeutics-to-report-first-quarter-2026-financial Thu, 07 May 26 08:30:00 -0400 https://ir.dwtx.com/news/press-releases/detail/154/dogwood-therapeutics-to-report-first-quarter-2026-financial <![CDATA[Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M]]> https://ir.dwtx.com/news/press-releases/detail/153/dogwood-therapeutics-announces-worldwide-development-and Thu, 23 Apr 26 09:00:00 -0400 https://ir.dwtx.com/news/press-releases/detail/153/dogwood-therapeutics-announces-worldwide-development-and <![CDATA[Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy]]> https://ir.dwtx.com/news/press-releases/detail/152/dogwood-therapeutics-announces-fda-acceptance-of-sp16 Wed, 15 Apr 26 09:00:00 -0400 https://ir.dwtx.com/news/press-releases/detail/152/dogwood-therapeutics-announces-fda-acceptance-of-sp16